CKD Bio is pursuing China National Medical Products Administration (NMPA) approval for its botulinum toxin product, targeting a 2027 market entry. The Seoul-based manufacturer has been building international presence beyond its home market, where it competes against AbbVie's Botox and Galderma's Dysport in the neuromodulator space.
Regulatory
CKD Bio Pursues China Botox Approval—2027 Launch Targeted
South Korean toxin maker seeks regulatory path into world's second-largest aesthetic market.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
2027 launch targeted for China market entry.
China's aesthetic market has grown into a critical battleground for toxin makers. Local players like Lanzhou Institute of Biological Products dominate on price, but multinational approval carries prestige and pricing power—particularly among tier-one city practitioners who value international-grade products and regulatory pedigree. CKD Bio's timeline suggests NMPA review is underway; approval would mark the company's first major Asian regulatory win outside South Korea and Japan.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.